This article is part of the Topical Collection on Risk, Prevention, and Screening
The uptake of selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) for the primary prevention of breast cancer is low, despite their proven efficacy in several randomized clinical trials. This review summarizes the latest data on physicians’ and women’s barriers to breast cancer preventive therapy. Physicians’ challenges include: identifying suitable candidates for preventive therapy, inadequate training and confidence in risk assessment and counselling, insufficient knowledge of risk-reducing medications, and lack of time. High-risk women fear medication side effects, and they often weigh experiences of others more heavily than statistical probabilities to guide their decision-making. Despite decision aid interventions to help women make an informed decision, acceptance of preventive therapy will remain low until: risk/benefit profiles are more favorable, physicians are better educated and skilled in having these discussions, and suitable biomarkers to monitor drug efficacy and better clinical risk prediction models to assess true individual risk are available.
NCCN clinical practice guidelines in oncology. Breast cancer risk reduction version 1.2016 https://www.nccn.org/professionals/physician_gls/pdf/breast_risk.pdf. An excellent overview of national evidence-based guidelines for breast cancer prevention.
Vogel VG, Costantino JP, Wickerham DL, et al. Update of the National Surgical Adjuvant Breast and Bowel Project study of tamoxifen and raloxifene (STAR) P-2 trial: preventing breast cancer. Cancer Prev Res (Phila). 2010;3:696–706.
Moyer VA, U.S. Preventive Services Task Force. Medications to decrease the risk for breast cancer in women: recommendations from the U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2013;159:698–708. PubMed
Corbelli J, Borrero S, Bonnema R, et al. Use of the Gail model and breast cancer preventive therapy among three primary care specialties. J Women’s Health. 2014;23:746–52. CrossRef
Carroll JC, Makuwaza T, Manca D, et al. Primary care providers’ experiences and views of personalized genomic medicine. Can Fam Phys. 2016 (in press).
Crew KD. Addressing barriers to uptake of breast cancer chemoprevention for patients and providers. Am Soc Clin Oncol Educ Book. 2015:e50–8. A thorough review of patient and provider barriers to preventive therapy.
Bambhroliya A, Chavez-MacGregor M, Brewster AM. Barriers to the use of breast cancer risk reduction therapies. J Natl Compr Cancer Netw. 2015;13:927–35.
Brewster AM, Davidson NE, McCaskill-Stevens W. Chemoprevention for breast cancer: overcoming barriers to treatment. Am Soc Clin Oncol Educ Book. 2012:85–90.
Paterniti DA, Melnikow J, Nuovo J, et al. “I’m going to die of something anyway”: women’s perceptions of tamoxifen for breast cancer risk reduction. Ethn Dis. 2005;15:365–72. PubMed
Holmberg C, Waters EA, Whitehouse K, et al. My lived experiences are more important than your probabilities: the role of individualized risk estimates for decision making about participation in the study of tamoxifen and raloxifene (STAR). Med Decis Mak. 2015;35:1010–22. CrossRef
Rahman RL, Pruthi S. Chemoprevention of breast cancer: the paradox of evidence vs. advocacy inaction. Cancer. 2012;4:1146–60. CrossRef
National Cancer Institute. Breast Cancer Risk Assessment Tool. Last updated 16 May 2011. www.cancer.gov/bcrisktool. Accessed 2 April 2016.
Constantino JP, Gail MH, Pee D, et al. Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst. 1999;91:1541–8. CrossRef
Harvie M, Howell A, Evans DG. Can diet and lifestyle prevent breast cancer: what is the evidence? Am Soc Clin Oncol Educ Book. 2015:e66-73.
Colditz GA, Bohlke K. Preventing breast cancer now by acting on what we already know. Breast. 2015;1:15009. npj.
Dite GS, MacInnis RJ, Bickerstaffe A, et al. Breast cancer risk prediction using clinical models and 77 independent risk-associated SNPs for women aged under 50 years: Australian breast cancer family registry. Cancer Epidemiol Biomarkers Prev. 2015;25:1–7.
- Physician and Patient Barriers to Breast Cancer Preventive Therapy
- Springer US
Neu im Fachgebiet Onkologie
Mail Icon II